To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38692 EQUILLIUM, INC. (Exact name of registrant as specified in its charter) | Delaware | 82-1554746 | | --- | --- | | (Sta ...

Exhibit 99.1 Hosted key opinion leader event highlighting the important role of the Aryl Hydrocarbon Receptor (AhR) in intestinal inflammation, the unmet medical need in ulcerative colitis, and the potential clinical utility of EQ504, a novel oral AhR modulator EQ504 Phase 1 clinical study initiation planned for mid-2026 LA JOLLA, California, November 13, 2025 – Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics ...

Closed financing of up to $50 million; initial tranche of $30 million provides runway through 2027 Hosted key opinion leader event highlighting the important role of the Aryl Hydrocarbon Receptor (AhR) in intestinal inflammation, the unmet medical need in ulcerative colitis, and the potential clinical utility of EQ504, a novel oral AhR modulator EQ504 Phase 1 clinical study initiation planned for mid-2026 LA JOLLA, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biot ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

PresentationGood afternoon, and welcome to the Equillium Bio Virtual KOL Event. [Operator Instructions] As a reminder, this call is being recorded, and a replay will be made available on the Equillium website following the conclusion of the event.Bruce SteelCo-Founder, CEO & Director Thank you very much. Good morning and/or good afternoon to everybody for joining today. We greatly appreciate you taking your time to learn more about the aryl hydrocarbon receptor and our EQ504 program. We will, during the cou ...

好的，这是对提供的电话会议记录的分析和总结。 纪要涉及的行业或公司 * 本次电话会议是 **Aquilium Bio** 公司举办的虚拟KOL活动 [1] * 会议核心是讨论**芳基烃受体** 以及公司的**EQ504项目** [2] * 公司专注于将EQ504项目首先应用于**溃疡性结肠炎** 的治疗 [3] * 行业背景是**免疫介导性疾病** 和**胃肠病学** 领域的药物研发 [3] 核心观点和论据 芳基烃受体作为有吸引力的药物靶点 * AHR是一个配体激活的转录因子，能控制与炎症和免疫反应相关的基因表达 [9] * AHR的激活可以**同时调节免疫细胞和非免疫细胞**，既能抑制炎症，又能促进组织修复和屏障完整性 [16][25] * 在肠道中，AHR的激活能诱导关键抗炎细胞因子**IL-10** 和促进屏障修复的细胞因子**IL-22** 的产生 [18][20] * AHR能稳定调节性T细胞，并可将促炎的Th17细胞转化为抗炎细胞 [24][25] * AHR还能直接作用于**上皮细胞**、**杯状细胞** 和**肠道干细胞**，促进粘膜愈合和组织再生 [18][25] * AHR的调节作用在皮肤疾病（如银屑病和特应性皮炎）中已得到临床验证，局部用药即可产生生物制剂类似的疗效 [50] 溃疡性结肠炎治疗领域存在高度未满足的医疗需求 * 尽管已有大量投资和多种获批药物，但现有疗法的缓解率仍然**低于30%** [3] * 即使是初治患者，在使用TNF拮抗剂等先进疗法后，最佳情况下的缓解率也仅能达到**50%** [34] * 对于治疗失败的患者，缓解率数字**非常低** [34] * 个性化医疗在IBD治疗中尚未成功，且IBD的基本病因仍不明确 [35] * 新的作用机制不断涌现，但尚无单一疗法能实现功能性治愈 [42][65] EQ504项目的优势与开发计划 * EQ504是内源性AHR激动剂**ITE** 的类似物，是一种强效且选择性高的AHR激动剂 [53] * 在报告基因实验中，EQ504的EC50为**0.67纳摩尔**，显著强于靛玉红（138纳摩尔）和靛蓝自然is [54] * 临床前数据显示，EQ504能诱导**IL-10** 和**IL-22** 的产生，促进上皮伤口愈合，并增加调节性T细胞的数量和功能 [55][57][58] * 在DSS结肠炎小鼠模型中，EQ504能防止体重减轻，诱导靶点参与，并改善组织学评分 [60][61][62][63] * 公司计划将EQ504开发为**口服结肠靶向制剂**，以最大化结肠组织暴露并最小化全身暴露，旨在提高疗效和安全性 [64][65] * 临床开发计划包括在**2026年中期**启动针对健康志愿者的SADMAD研究，并可能增加UC患者队列以快速获得概念验证 [66][67] * EQ504可作为**口服生物制剂前疗法**，用于治疗失败的患者，或与多种其他疗法（如抗整合素、TL1A、JAK抑制剂等）进行**联合治疗**，以提升疗效天花板 [65] 其他重要但可能被忽略的内容 * 来自**靛蓝自然is** 的临床数据为AHR调节在UC中的疗效提供了强有力的概念验证：在一项日本多中心试验中，临床缓解率达到**50%**；在一项针对难治性患者的研究中，第8周缓解率为**27%** [51][52] * **TL1A** 作为一种新的作用机制受到关注，其作为调节性细胞因子可放大免疫反应并可能具有抗纤维化作用，在UC和克罗恩病中均显示出活性 [36][37][44] * **联合疗法** 被视为提高疗效潜力的重要途径，例如J&J的VEGA研究显示了guselkumab和golimumab的叠加效应 [43] * 治疗终点正在演变，**组织病理学愈合** 可能比内镜愈合更能反映有意义的疾病改善，并可能成为未来的治疗目标 [75][76][102][103] * 关于**Obefazimod**，会议提到其确实具有AHR调节特性，但效力低于EQ504 [89][90] 其III期诱导研究显示效应大小约为**15%**，处于中等水平 [82][83] * 在结肠靶向制剂开发中，需要考虑UC患者肠道**pH值变化** 的挑战，可能需采用**双重触发机制**（如pH和微生物组）来确保可靠的药物释放 [118][119][120][121] * 有观点认为UC主要是一种**局部疾病**，通过局部作用实现粘膜愈合后，肠外表现也会随之改善，这支持了结肠靶向给药的策略 [124][126]

Virtual KOL Event to Discuss EQ504: A Novel Aryl Hydrocarbon Receptor (AhR) Modulator for Ulcerative Colitis 1 November 5, 2025 Forward-Looking Statements and Other Disclaimers 3 This presentation contains forward-looking statements about Equillium, Inc. (the "Company"). In some cases, you can identify forward-looking statements by the words "will," "expect," "intend," "plan," "objective," "believe," "estimate," "potential," "continue" and "ongoing," or the negative of these terms, or other comparable termi ...

LA JOLLA, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that management will participate in the following upcoming investor conferences: Stifel Healthcare Conference Format:Company Presentation & 1x1 MeetingsDate:Wednesday, November 12, 2025Time:3:20-3:50 PM EDT Jefferies Global Healthcare Confe ...

LA JOLLA, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that on October 31, 2025, the Compensation Committee of Equillium’s Board of Directors granted inducement awards consisting of nonstatutory stock options to purchase a total of 7,200 shares of common stock to a new employee under Equillium’s 2024 Inducement Plan. The Compensation Committee approved the st ...